There have been significant improvements in the outcome of other subtypes of breast cancer, including ER-positive/HER2 overexpressed tumors, attributed to the addition of targeted therapy, including hormonal agents and trastuzumab [11, 12]. This evidence concerns the gene ERBB2 and breast carcinoma.